[go: up one dir, main page]

WO2007138116A3 - Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus - Google Patents

Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus Download PDF

Info

Publication number
WO2007138116A3
WO2007138116A3 PCT/EP2007/055425 EP2007055425W WO2007138116A3 WO 2007138116 A3 WO2007138116 A3 WO 2007138116A3 EP 2007055425 W EP2007055425 W EP 2007055425W WO 2007138116 A3 WO2007138116 A3 WO 2007138116A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pharmaceutical composition
viral infections
tumor diseases
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/055425
Other languages
English (en)
French (fr)
Other versions
WO2007138116A2 (de
Inventor
Ulrich Schubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virologik GmbH
Original Assignee
Virologik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0712459-7A priority Critical patent/BRPI0712459A2/pt
Priority to CA002654276A priority patent/CA2654276A1/en
Priority to JP2009512618A priority patent/JP2009538881A/ja
Priority to EP07765312A priority patent/EP2029125A2/de
Priority to MX2008015259A priority patent/MX2008015259A/es
Priority to AU2007267082A priority patent/AU2007267082A1/en
Application filed by Virologik GmbH filed Critical Virologik GmbH
Publication of WO2007138116A2 publication Critical patent/WO2007138116A2/de
Publication of WO2007138116A3 publication Critical patent/WO2007138116A3/de
Priority to IL195611A priority patent/IL195611A0/en
Anticipated expiration legal-status Critical
Priority to US12/325,598 priority patent/US20090156473A1/en
Priority to NO20085243A priority patent/NO20085243L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft eine pharmazeutische Zusammensetzung, die als wirksame Komponenten mindestens einen Proteasom-Inhibitor und einen Inhibitor von Proteinfaltungsenzymen enthält. Diese Mittel sind zur Behandlung von akuten und chronischen Infektionen mit für Mensch und Tier pathogenen Viren geeignet.
PCT/EP2007/055425 2006-06-01 2007-06-01 Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus Ceased WO2007138116A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002654276A CA2654276A1 (en) 2006-06-01 2007-06-01 Pharmaceutical composition for treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein degradation
JP2009512618A JP2009538881A (ja) 2006-06-01 2007-06-01 タンパク質フォールディング及びタンパク質分解の阻害による、ウィルス感染及び／又は腫瘍疾患の治療のための医薬組成物
EP07765312A EP2029125A2 (de) 2006-06-01 2007-06-01 Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus
MX2008015259A MX2008015259A (es) 2006-06-01 2007-06-01 Composicion farmaceutica para el tratamiento de infecciones virales y/o enfermedades tumorales por medio de la inhibicion del plegamiento proteico y la degradacion proteica.
AU2007267082A AU2007267082A1 (en) 2006-06-01 2007-06-01 Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown
BRPI0712459-7A BRPI0712459A2 (pt) 2006-06-01 2007-06-01 composiÇço farmacÊutica para tratamento de infecÇÕes virais e/ou doenÇas de tumor atravÉs de inibiÇço de dobra de proteÍna e degradaÇço de proteÍna
IL195611A IL195611A0 (en) 2006-06-01 2008-11-30 Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown
US12/325,598 US20090156473A1 (en) 2006-06-01 2008-12-01 Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown
NO20085243A NO20085243L (no) 2006-06-01 2008-12-15 Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006026464.9 2006-06-01
DE102006026464A DE102006026464A1 (de) 2006-06-01 2006-06-01 Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus

Publications (2)

Publication Number Publication Date
WO2007138116A2 WO2007138116A2 (de) 2007-12-06
WO2007138116A3 true WO2007138116A3 (de) 2008-05-08

Family

ID=38626699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/055425 Ceased WO2007138116A2 (de) 2006-06-01 2007-06-01 Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus

Country Status (15)

Country Link
US (1) US20090156473A1 (de)
EP (1) EP2029125A2 (de)
JP (1) JP2009538881A (de)
KR (1) KR20090048403A (de)
CN (1) CN101453998A (de)
AU (1) AU2007267082A1 (de)
BR (1) BRPI0712459A2 (de)
CA (1) CA2654276A1 (de)
DE (1) DE102006026464A1 (de)
IL (1) IL195611A0 (de)
MX (1) MX2008015259A (de)
NO (1) NO20085243L (de)
RU (1) RU2008152796A (de)
WO (1) WO2007138116A2 (de)
ZA (1) ZA200810531B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
CA2562411A1 (en) 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
SG185963A1 (en) * 2004-05-10 2012-12-28 Onyx Therapeutics Inc Compounds for enzyme inhibition
CN103230394B (zh) 2004-12-03 2016-04-20 达纳-法伯癌症研究公司 治疗肿瘤性疾病的化合物及其用途
US7687456B2 (en) 2005-11-09 2010-03-30 Proteolix, Inc. Compounds for enzyme inhibition
EP2484688B1 (de) * 2006-06-19 2016-06-08 Onyx Therapeutics, Inc. Peptidepoxyketone für proteasom-hemmung
WO2008095195A2 (en) 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
US20080280968A1 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
DE102007031397A1 (de) 2007-07-05 2009-01-08 D2O Bioscience Group Ltd. Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut
MX2010003732A (es) * 2007-10-04 2010-08-09 Onyx Therapeutics Inc Inhibidores de peptido cetona epoxi de proteasa cristalina y la sintesis de ceto-epoxidos de aminoacido.
JP5468015B2 (ja) * 2008-01-08 2014-04-09 アクセリア ファーマシューティカルズ 抗菌ペプチド系に対する作動薬
JP2011519975A (ja) 2008-05-12 2011-07-14 ネレアス ファーマシューティカルズ インコーポレイテッド プロテアソーム阻害剤としてのサリノスポラミド誘導体
PE20120059A1 (es) * 2008-10-21 2012-02-27 Onyx Therapeutics Inc Combinaciones farmaceuticas con epoxicetonas peptidicas
DE102009003942A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
DE102009003992A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Respirationstraktes
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
JP2013500265A (ja) * 2009-07-23 2013-01-07 ザ トラスティーズ オブ プリンストン ユニバーシティ 抗ウイルス剤として用いられるｍＴＯＲキナーゼ阻害剤
WO2011009961A1 (en) * 2009-07-24 2011-01-27 Virologik Gmbh Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
CN102051407B (zh) * 2009-11-09 2012-12-12 中国医学科学院医药生物技术研究所 Hiv-1前体蛋白早成熟化诱导剂的筛选方法
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
US9102942B2 (en) 2010-02-04 2015-08-11 EWHA University—Industry Collaboration Foundation Pharmaceutical composition for inhibiting abnormal proliferation of cells
US9359398B2 (en) 2010-03-01 2016-06-07 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
WO2011136905A2 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
JP6028968B2 (ja) * 2012-02-24 2016-11-24 学校法人順天堂 抗インフルエンザウイルス剤
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
CN105477007B (zh) * 2014-09-15 2020-02-18 中国医学科学院药物研究所 大环内酯类药物在抗丝状病毒感染中的应用
CN105675572B (zh) * 2016-03-15 2018-09-14 四川大学华西医院 一种肺癌筛查试剂盒
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11266675B2 (en) * 2018-04-30 2022-03-08 City University Of Hong Kong Methods of treatment of viral infection and uses of anti-HSC70 inhibitors
CN108635584B (zh) * 2018-05-22 2021-12-21 广州威溶特医药科技有限公司 蛋白酶体抑制剂和甲病毒在制备抗肿瘤药物中的应用
CN110133286A (zh) * 2019-05-20 2019-08-16 吉林大学 Hsp60基因作为靶点在脑膜炎治疗中的医用用途
PL4129290T3 (pl) 2020-03-26 2025-10-13 Shin Poong Pharmaceutical Co., Ltd. Kompozycja farmaceutyczna zawierająca pironarydynę lub jej sól, artemizyninę lub jej pochodną lub kombinację ich obu do zapobiegania lub leczenia choroby układu oddechowego wywołanej przez koronawirusa
CN111514299A (zh) * 2020-04-29 2020-08-11 广州中医药大学科技产业园有限公司 一种用于防治肺炎的组合物及其在制备用于防治肺炎的药物中的应用
WO2021231397A1 (en) * 2020-05-13 2021-11-18 The Regents Of The University Of California Thiosaccharides for use in treating coronavirus infection
WO2021263139A1 (en) * 2020-06-26 2021-12-30 Duke University Methods of treating coronavirus infection using hsp90 inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999022729A1 (en) * 1997-10-31 1999-05-14 Centre De Recherche Du Centre Hospitalier De L'universite De Montreal The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
WO2002030455A2 (de) * 2000-10-12 2002-04-18 Viromics Gmbh Mittel zur behandlung von virus-infektionen
US20020049157A1 (en) * 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
WO2002080907A1 (en) * 2001-04-03 2002-10-17 Millennium Pharmaceuticals, Inc. Combination of lactacystin analog and immunosuppressive drug for the prolongation of allograft survival
WO2005063281A2 (de) * 2003-12-31 2005-07-14 Viromics Gmbh Mittel zur hemmung der virusreplikation durch regulation der proteinfaltung
WO2007059116A2 (en) * 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Geldanamycin derivatives and pharmaceutical compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
WO2005115431A2 (en) * 2004-05-24 2005-12-08 Adonia Papathanassiu Methods for inhibiting proteasome and heat shock protein 90
EP1874297A4 (de) * 2005-04-29 2009-04-22 Kosan Biosciences Inc Verfahren zur behandlung mehrerer myelome mithilfe von 17-aag oder 17-ag oder eines prodrugs oder von allem in kombination mit einem proteasom-hemmer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999022729A1 (en) * 1997-10-31 1999-05-14 Centre De Recherche Du Centre Hospitalier De L'universite De Montreal The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US20020049157A1 (en) * 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
WO2002030455A2 (de) * 2000-10-12 2002-04-18 Viromics Gmbh Mittel zur behandlung von virus-infektionen
WO2002080907A1 (en) * 2001-04-03 2002-10-17 Millennium Pharmaceuticals, Inc. Combination of lactacystin analog and immunosuppressive drug for the prolongation of allograft survival
WO2005063281A2 (de) * 2003-12-31 2005-07-14 Viromics Gmbh Mittel zur hemmung der virusreplikation durch regulation der proteinfaltung
WO2007059116A2 (en) * 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Geldanamycin derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
NO20085243L (no) 2009-02-27
ZA200810531B (en) 2009-11-25
JP2009538881A (ja) 2009-11-12
CA2654276A1 (en) 2007-12-06
KR20090048403A (ko) 2009-05-13
DE102006026464A1 (de) 2007-12-06
MX2008015259A (es) 2009-03-26
EP2029125A2 (de) 2009-03-04
AU2007267082A1 (en) 2007-12-06
BRPI0712459A2 (pt) 2012-07-31
CN101453998A (zh) 2009-06-10
WO2007138116A2 (de) 2007-12-06
IL195611A0 (en) 2009-09-01
US20090156473A1 (en) 2009-06-18
RU2008152796A (ru) 2010-07-20

Similar Documents

Publication Publication Date Title
WO2007138116A3 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
EP2452935A3 (de) Tetracyxlin-Derivate zur Behandlung bakterieller, viraler und parasitärer Infektionen
IL200116A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
WO2008115281A3 (en) Compounds for treating viral infections
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
EA200901308A1 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
EA200801163A1 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
WO2008095040A3 (en) 2-5a derivatives and their use as anti-cancer, anti-viral and anti-parasitic agents
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MY157860A (en) Prevention and treatment of secondary infections following viral infection
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
EA200900020A1 (ru) Фармацевтическая композиция с синергетическим противосудорожным эффектом
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2007133865A3 (en) Hcv/hiv inhibitors an their uses
EA201101477A1 (ru) Органические соединения и их применение
WO2008070268A3 (en) Pharmaceutical compositions
WO2007121124A3 (en) Hcv inhibitors comprising beta amino acids and their uses
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
WO2007128086A3 (en) Novel viral replication inhibitor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780019706.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07765312

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008111901

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 9869/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/015259

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2654276

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009512618

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 573817

Country of ref document: NZ

Ref document number: 2007267082

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007765312

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087032197

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: A20081713

Country of ref document: BY

ENP Entry into the national phase

Ref document number: 2008152796

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2007267082

Country of ref document: AU

Date of ref document: 20070601

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0712459

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081201